A team linked to Duke University and the UNC Alzheimer’s Disease Research Center has found that a simple brush swab of the nasal lining can pick up molecular and immune cell changes tied to Alzheimer’s disease, even in people who show no memory problems. The findings, drawn from a preprint study analyzing cells from the olfactory cleft, suggest that this minimally invasive technique could one day help identify the disease years before cognitive decline begins. If validated in larger trials, the approach could reshape how clinicians screen for Alzheimer’s by replacing costly, uncomfortable procedures with a quick office visit.
What the Nasal Brush Biopsy Reveals
The study, described in detail in a recent preprint, used a cytology brush inserted through the nose to collect cells from the olfactory cleft, the narrow region high inside the nasal cavity where smell-sensing neurons reside. Researchers then compared samples from three groups: healthy controls, individuals with pre-clinical Alzheimer’s defined by typical cognition but atypical cerebrospinal fluid biomarkers, and patients already experiencing clinical symptoms.
That middle group is the most telling. These participants had no memory complaints and would pass a standard cognitive screening. Yet their nasal tissue already carried distinct molecular signatures associated with Alzheimer’s pathology. The biopsies revealed changes in both nerve cells and immune cells that tracked with biomarker-defined disease stages, according to the analysis posted through Cold Spring Harbor Laboratory. The researchers described brush biopsies as “a practical strategy” for capturing these signals, language that reflects how low the barrier to entry is: no surgery, no spinal tap, no radioactive tracer injection.
Within the sampled tissue, the team reported shifts in gene expression tied to inflammation, cellular stress, and synaptic function. Immune cells in the olfactory lining appeared activated in patterns that mirrored known Alzheimer’s-related changes in the brain’s microglia. Neuronal markers also showed stage-dependent differences, suggesting that the olfactory epithelium is not just a bystander but a dynamic participant in the disease process. Importantly, these alterations were detectable even in individuals whose thinking and memory remained clinically normal.
Why the Olfactory System Matters for Alzheimer’s
The nose is not an obvious place to look for a brain disease. But the olfactory epithelium is one of the few spots where neurons are directly exposed to the environment and continuously regenerate throughout life. Scientists have long known that smell loss often precedes Alzheimer’s diagnosis by several years, and the olfactory system shares molecular pathways with brain regions hit hardest by the disease. What this Duke-linked work adds is direct cellular evidence: the tissue lining the olfactory cleft does not just lose function passively but actively reflects the same immune and neuronal disruptions found deeper in the brain.
This distinction matters for detection strategy. Current gold-standard methods for identifying early Alzheimer’s rely on either lumbar puncture to measure cerebrospinal fluid proteins or PET imaging to visualize amyloid plaques. Both are expensive, require specialized facilities, and carry enough discomfort or risk to discourage routine screening. A brush biopsy performed during a standard nasal endoscopy, by contrast, could be done in a primary care or ENT office with minimal patient burden, provided staff are trained and appropriate equipment is available.
The anatomical link between the olfactory epithelium and central nervous system also strengthens the biological plausibility of the approach. Olfactory neurons send projections directly into brain regions that are vulnerable to Alzheimer’s pathology. If abnormal proteins and inflammatory cascades are already active in those circuits, it is reasonable that related changes would be visible in the peripheral tissue from which those neurons arise. The new data suggest that this peripheral window may be sensitive enough to capture disease-related shifts well before overt cognitive decline.
The Duke Clinical Trial Behind the Research
The preprint is not an isolated academic exercise. It connects to an active Duke-sponsored clinical trial registered as NCT07021040, which is collecting olfactory lining biopsies using both punch technique and cytology brush methods. The trial involves nasal endoscopy and biopsy procedures and is designed to measure outcomes longitudinally, meaning researchers plan to track participants over time rather than relying on a single snapshot.
That longitudinal design is significant. A one-time biopsy can show correlation between nasal tissue changes and Alzheimer’s biomarkers, but repeated sampling could reveal whether those changes progress in step with disease advancement. If the nasal signatures reliably worsen before cognitive symptoms appear, clinicians would have a practical, repeatable monitoring tool. Lead investigator Bradley J. Goldstein, identified through Duke’s institutional research database, is listed as a principal figure on the work and has previously focused on the interface between olfactory biology and neurodegenerative disease.
Trial registration materials indicate that participants undergo standardized cognitive assessments alongside nasal procedures, allowing researchers to link tissue-level changes with both biomarker status and clinical performance. Over time, that structure could help answer whether specific molecular patterns in the olfactory lining forecast who will progress from pre-clinical stages to mild cognitive impairment or dementia, and on what timeline.
What Peer Review Still Needs to Settle
The research carries a significant caveat that early-stage findings often gloss over. The study remains a preprint, published through the PubMed-indexed record but not yet fully vetted by journal peer review. Preprints allow rapid dissemination of results, but they lack the independent scrutiny that formal publication provides. External experts will need to examine the statistical methods, reproducibility of the molecular signatures, and potential confounders such as age, coexisting nasal disease, or medication use.
Several open questions remain. The preprint groups participants by biomarker status rather than by eventual clinical outcome, so it is not yet clear how well nasal signatures predict who will actually develop dementia versus who might carry abnormal biomarkers without progressing. Sample sizes in early-phase studies like this one are typically small, and replication across diverse populations will be essential before any clinical rollout. The technique also requires nasal endoscopy, which, while far less invasive than a spinal tap, still demands trained personnel and equipment that not every clinic has on hand.
Another unresolved issue is standardization. For a nasal biopsy test to be clinically useful, laboratories would need clear protocols for sample collection, processing, and analysis, along with reference ranges that distinguish normal aging from early disease. Peer review and subsequent validation studies will be crucial for determining which specific molecular markers are robust enough to form the basis of a diagnostic assay.
How This Fits the Broader Push for Early Detection
The timing of this research aligns with a broader shift in Alzheimer’s treatment philosophy. New anti-amyloid drugs work best, and in some cases only qualify patients for treatment, when the disease is caught early. That has created urgent demand for screening tools that can be deployed widely and affordably, not just at academic medical centers with PET scanners and spinal tap suites. A nasal brush biopsy, if validated, would fit that gap precisely by offering a middle ground between highly specialized imaging and simple but less specific blood tests.
There is also a conceptual challenge worth examining. Most current Alzheimer’s biomarker research focuses on proteins in blood or cerebrospinal fluid. The Duke-affiliated team’s approach is different because it looks at living tissue, capturing not just protein markers but also the cellular context in which those markers arise. That could reveal complex interactions between neurons and immune cells that are difficult to infer from fluid samples alone.
Institutional infrastructure may help push this work forward. Platforms such as Scholars@Duke centralize information about researchers, publications, and ongoing studies, making it easier for collaborators, funders, and potential participants to track developments in emerging fields like olfactory-based diagnostics. As additional data accumulate from the current trial and any follow-on studies, such systems can help ensure that both promising results and negative findings are visible to the broader community.
For now, the nasal brush biopsy remains an experimental tool, not a clinic-ready test. But the concept it embodies, that accessible peripheral tissues might mirror deep brain pathology, could have implications beyond Alzheimer’s, potentially informing research into other neurodegenerative and psychiatric conditions. Whether this particular method ultimately becomes part of routine care will depend on the answers to questions that only larger, peer-reviewed studies can provide. How accurate is it? How early can it detect disease? And can it do so in a way that is equitable and scalable across health systems?
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
